Financial Data and Key Metrics Changes - Net sales for Q3 2019 were $171 million, representing a 4% increase compared to the prior year, while adjusted diluted earnings per share was $0.30 [7][17] - Full year sales expectations were revised down from 8% to 10% growth to 5% to 7% growth due to back orders and challenges from the new IT system [9][23] - Adjusted diluted earnings per share guidance was lowered from $1.15 to $1.25 to a range of $1 to $1.10 [9][23] Business Line Data and Key Metrics Changes - COOLIEF experienced over 20% growth, marking its highest quarterly growth this year, although it was slightly below expectations due to a shift from multi-probe kits to standard kits [10][17] - Acute Pain performed in line with expectations, but ON-Q sales were down mid-single digits for the quarter [19] - Chronic Care business faced challenges due to product back orders and supply chain issues, but is expected to continue growing in the mid-single digits [20] Market Data and Key Metrics Changes - International sales in EMEA and Latin America missed expectations due to back orders and supply chain challenges, but the Asia-Pacific region saw double-digit growth [9][21] - The company faced lower chronic care order volumes from U.S. distributors, impacting quarterly results [8][20] Company Strategy and Development Direction - The company is focused on accelerating organic growth, pursuing M&A, and managing costs effectively [14] - Recent acquisitions, including Endoclear and Summit Medical Products, are expected to strengthen the business and accelerate growth [12][13] - The company aims to stabilize its IT system and processes while addressing operational issues to enhance efficiency [16] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in Q3 but expressed confidence in the long-term strategy and ability to address operational gaps [6][9] - The company is committed to investing in growth areas like COOLIEF and Corpak while managing costs prudently [14][23] - Management expects to see improvements in operational efficiency and sales as back orders are resolved [39] Other Important Information - Adjusted gross margin for the quarter was 57%, which was unfavorable compared to the previous year due to IT system implementation and increased distribution costs [21] - Free cash flow was an outflow of $24 million due to one-time spending and increased working capital related to the new IT system [22] Q&A Session Summary Question: Impact of IT system integration on gross margin - Management explained that the IT system integration caused plant downtime and increased distribution costs, which negatively impacted gross margin [25][28] Question: Future investments in COOLIEF - Management indicated that while there will be some investment in COOLIEF, it will not be as aggressive as in previous years, focusing on maintaining momentum and expanding distribution [29][33] Question: Headwinds moving into Q4 - Management acknowledged that backlog issues would carry into Q4, but they are making progress in addressing these challenges [37][39] Question: Changes in reimbursement levels for COOLIEF - Management clarified that the new reimbursement rate for hospital outpatient departments is favorable compared to previous proposals, which should support growth [41][70] Question: CFO search update - Management provided an update on the CFO search, indicating progress with candidates and that the current team is performing well in the interim [63]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State ...

Avanos Medical, Inc. (NYSE:AVNS) Q2 2019 Results Conference Call August 6, 2019 9:00 AM ET Company Participants Dave Crawford – Vice President of Investor Relations Joe Woody – Chief Executive Officer Conference Call Participants Rick Wise – Stifel Ravi Misra – Berenberg Capital Markets Larry Keusch – Raymond James Matthew Mishan – KeyBanc David Lewis – Morgan Stanley Chris Cooley – Stephens Kristen Stewart – Barclays Operator Good day and welcome to the Avanos Second Quarter Earnings Conference Call and We ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or o ...

Avanos Medical, Inc. (NYSE:AVNS) Q1 2019 Earnings Conference Call May 7, 2019 9:00 AM ET Company Participants David Crawford - VP, FP&A and IR and Treasurer Joseph Woody - CEO & Director Steven Voskuil - SVP & CFO Conference Call Participants Lawrence Keusch - Raymond James & Associates Ravi Misra - Berenberg Frederick Wise - Stifel, Nicolaus & Company Jonathan Demchick - Morgan Stanley Kristen Stewart - Barclays Bank Matthew Mishan - KeyBanc Capital Markets Christopher Cooley - Stephens Inc. Operator Good ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State o ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2018 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36440 Avanos Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) (I. ...